Patrick Langlois Net Worth

Patrick Langlois biography

Dr. Patrick J. Langlois, Ph.D. is directors of the Company since April 2006. Since March 2005, Dr. Langlois has served as the General Partner of PJL Conseils, a consulting firm specializing in strategy, corporate development and mergers and acquisitions. From 2002 to 2004, he served as Vice Chairman of the Management Board and Chief Financial Officer at Aventis S.A., and from 1999 to 2002 as its Executive Vice President and Chief Financial Officer. At Aventis, Dr. Langlois was responsible for finance and corporate development functions, as well as three global businesses: dermatology, protein therapeutics and animal health. From 1990 to 1999, Dr. Langlois was employed by Rhône-Poulenc Group, most recently as Chief Financial Officer and a Member of the Executive Committee. From 1990 to 1996, he was employed by Rhône-Poulenc Rorer, a NYSE-listed pharmaceutical company, most recently as Chief Financial Officer. Dr. Langlois received a License degree from the University of Rennes, a Ph.D. degree in Economics from the University of Rennes and was awarded a Diploma in Higher Banking Studies from the Centre d’Etudes Supérieures de Banque in France. Because of Dr. Langlois’ extensive experience in the healthcare sector, including an executive position as chief financial officer of a NYSE-listed company as well as his relationships with institutional investors and investment banks in the United States and Europe, we believe he is able to make valuable contributions to our board of directors.

How old is Patrick Langlois?

Patrick Langlois is 70, he's been the Director of Scynexis Inc since 2006. There are no older and 15 younger executives at Scynexis Inc.

What's Patrick Langlois's mailing address?

Patrick's mailing address filed with the SEC is C/O SCYNEXIS, INC.,, 3501 C TRICENTER BOULEVARD, DURHAM, NC, 27713.

Insiders trading at Scynexis Inc

Over the last 11 years, insiders at Scynexis Inc have traded over 4,708,140$ worth of Scynexis Inc stock and bought 2,173,590 units worth 13,469,713$ . The most active insiders traders include Advisors Llcperceptive Life...、Patrick Machado、Marco Taglietti. On average, Scynexis Inc executives and independent directors trade stock every 49 days with the average trade being worth of 64,694$. The most recent stock trade was executed by Marco Taglietti on 26 April 2022, trading 75,000 units of SCYX stock currently worth 225,000$.

What does Scynexis Inc do?

scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.

Scynexis Inc executives and stock owners

Scynexis Inc executives and other stock owners filed with the SEC include:

• Dr. Marco Taglietti M.D.,
  CEO, Pres & Director
• Dr. Marco Taglietti,
  CEO, Pres & Director
• David Gonzalez Angulo,
  Chief Medical Officer
• Eric Francois,
  Chief Financial Officer
• Christine R. Coyne M.B.A.,
  Chief Commercial Officer
• Philippe Tinmouth,
  Director
• Jean-Yves Nothias,
  Director
• Guy Macdonald,
  Director
• Patrick Langlois,
  Director
• David Hastings,
  Director
• Ann Hanham,
  Director
• Steven Gilman,
  Director
• Laurent Arthaud,
  Director
• Armando Anido,
  Director
• David Angulo,
  Chief Medical Officer
• Scott Sukenick,
  General Counsel
• Nkechi Azie,
  Vice President - Clinical Development
• Jim Maffezzoli,
  Vice President of Sales and Marketing
• Eric Francois,
  Chief Financial Officer
• Marco Taglietti,
  President, Chief Executive Officer, Director
• Pamela Kirby,
  Chairman of the Board
• Debbie Etchison,
  Exec. Director of Communications
• Lawrence R. Hoffman CPA, Esq.,
  Interim CFO & Principal Accounting Officer
• Dr. Rajeshwar Motheram,
  Sr. VP of Pharmaceutical Devel. & Supply Chain
• Scott Sukenick J.D.,
  Gen. Counsel & Corp. Sec.
• Patrick Machado,
  Director
• Marion Mc Court,
  Director
• Jr. Charles F Osborne,,
  Chief Financial Officer
• Biopharma Partners Ii Lpalt...,
  
• Carole Sable,
  Chief Medical Officer
• Capital Ii Ventech,
  10% owner
• Biotechnology Fund Fcpr,
  10% owner
• Eileen Pruette,
  General Counsel
• Genavent F.C.P.R.,
  10% owner
• Mounia Chaoui,
  Director
• Edward Penhoet,
  Director
• Yves J Ribeill,
  President and CEO
• Advisors Llcperceptive Life...,
  
• Christine Coyne,
  Chief Commercial Officer
• Ivor Macleod,
  Chief Financial Officer